Nutricosmetics Market Matures with Advanced Formulation Science, Clinical Validation

Nutraceuticals World (NW): What trends are currently shaping the nutricosmetics market and which directions do you see the category heading over the next few years?

Uroš Gotar, Chief Innovation Officer, TOSLA: The market is entering a phase of consolidation and professionalization.

Driven by a broader market expansion where the global dietary supplements industry is at $200 billion valuation in 2026, with an accelerated 9.5% CAGR projected through 2030 (Grand View Research, 2026), growth remains strong across key segments such as collagen-based products, hydration, and skin longevity, but the real shift is structural. The category is moving away from fragmented, single-benefit products toward integrated, multi-functional solutions that address several consumer needs in one format. This shift is supported by consumer behavior, with 51% of global nutritional supplement users preferring supplements that offer multiple benefits. (Nutiani data shows nutrition consumers prioritize value and efficacy)

At the same time, expectations around substantiation are increasing. Both consumers and regulators are pushing for a higher level of scientific validation, which will drive a clear separation between clinically supported products and purely marketing-led claims.

Over the next three to five years, we expect the category to become more disciplined defined by fewer, stronger products with clear positioning, validated performance, and formats that support long-term use.

NW: Can you discuss how TOSLA approaches R&D, innovation, and manufacturing, as well as your capabilities and what you offer to the marketplace?

Gotar: Our approach is based on integration.

We bring together formulation science, sensory optimization, clinical validation, and high-volume production into a single development platform. A key component of this is our internal R&D library, which includes extensive formulation data, stability testing, sensory benchmarks, and clinical insights accumulated across thousands of development cycles.

This gives us a strong starting point for new projects. Rather than building from zero, we work with validated systems and adapt them to partner requirements, which significantly improves efficiency and reduces risk.

From a market perspective, we operate as a full-service CDMO partner. That includes concept development, formulation, flavor engineering, clinical validation, and scalable manufacturing. Our infrastructure is specifically designed for liquid formats, with automated production lines that allow us to deliver both flexibility and volume.

The objective is clear: connect innovation with execution in a way that enables our partners to compete effectively.

NW: Why are liquid delivery formats gaining traction? What advantages and challenges do they present compared to other formats?

Gotar: Liquid formats are gaining traction because they address both physiological and behavioral factors.

From a technical perspective, liquids enable the delivery of clinically relevant doses in a single serving and allow for faster absorption compared to traditional solid forms.

From a consumer perspective, the drivers are convenience and usability. Industry data shows that ease of use is now one of the leading decision factors in supplement selection, alongside scientific credibility. Liquids align well with this trend — they are intuitive, require minimal effort, and integrate easily into daily routines.

However, liquids also introduce significant formulation challenges. These include managing ingredient interactions, maintaining stability over shelf life, and ensuring consistent taste across batches and markets.

This complexity is why liquids require dedicated expertise. They are not simply an alternative format — they represent a fundamentally different development and manufacturing discipline.

NW: How important is flavor innovation in today’s nutricosmetics category?

Gotar: Flavor innovation is directly linked to product performance. Many of the active ingredients used in nutraceuticals — collagen peptides, minerals, botanical extracts — carry inherent sensory challenges. If these are not properly managed, they limit both formulation flexibility and consumer acceptance.

At TOSLA, we address this through our VELIOUS™ Flavor Technology, which enables the development of sugar-free liquid formulations with complex active profiles while maintaining a consistent and pleasant sensory experience.

From a commercial standpoint, flavor has a measurable impact on repeat purchase and retention. If a product is not palatable, adherence drops, and that directly affects both perceived efficacy and long-term brand performance.

In that sense, flavor is not a secondary consideration but rather a functional requirement. In fact, looking across our global portfolio, our clients experience an average customer retention rate of 60% and repeat purchase of 12.2 500ml bottles per customer per year. Proving that when you solve the sensory barrier, you secure long-term consumer loyalty.

NW: TOSLA emphasizes speed to market, from formulation to production. How does the company achieve that efficiency?

Gotar: Speed to market is the result of structured processes and accumulated knowledge.

Our R&D library is a critical enabler. Because we have access to a large body of validated formulations, stability data, and sensory systems, we can significantly reduce the initial development phase and focus on optimization rather than basic formulation.

In parallel, we operate with cross-functional alignment from the outset. R&D, regulatory, sensory, and production teams work within the same framework, which minimizes delays typically caused by sequential development processes.

On the manufacturing side, our facilities are designed for flexibility, with the capacity to transition from pilot batches to large-scale production efficiently.

This combination allows us to shorten development timelines while maintaining consistency and quality — both of which are essential in a competitive market environment.

NW: What differentiates TOSLA from other supplement manufacturers and suppliers?

Gotar: The key difference lies in positioning and focus.

We are not a generalist manufacturer. We are a liquid-first CDMO partner with deep expertise in formulation, flavor engineering, and scalable production of liquid ingestibles.

Secondly, our model extends beyond manufacturing. We integrate formulation development, clinical validation, and production into a single system, which allows us to support partners at every stage of the product lifecycle.

Finally, we actively work across the value chain, including collaborations with ingredient manufacturers. Our work with Geltor is a strong example — taking advanced biotech ingredients and translating them into finished products that are stable, scalable, and suitable for daily use.

This ability to bridge scientific innovation and real-world application is where the majority of value is created, and it is where we focus our efforts as a company.